Recent Patents on Modified Release Oral Dosage Forms

Abstract

Background: Conventional oral dosage forms have limited bioavailability and frequent dosing of the drug is needed to maintain the effective therapeutic concentration in the body. This results in poor patient compliance and fluctuations in the plasma drug levels, especially in the chronic diseases and disorders.


Objective: To overcome such problems and to enhance the efficiency and bioavailability of the drug, modified drug delivery systems such as extended release delivery systems (controlled release; sustained release) and delayed release delivery systems are developed which can prolong the release and hence action of the drug in the body.


Methods: Through this review, we throw the light on recent patents and patent applications on modified release systems pertaining to oral dosage forms.  The various free patent search databases were used to collect and analyze the information on modified release delivery systems.


Results: Modified release systems such as extended release and delayed release delivery systems have been found to be of great significance due to their advantages over immediate release dosage forms. These systems are formulated using various approaches, different types of release controlling polymers such as natural, semisynthetic and synthetic polymers and found to avoid the limitations of conventional oral dosage forms.


Conclusion: Modified drug release systems have potential especially, in case of the chronic diseases, mental health disorders and lifestyle diseases and disorders. These systems have unique commercial advantages which will sustain the interest of both the researchers and the pharmaceutical companies.


Keywords: Modified release systems, extended release systems, controlled release systems, sustained release systems, delayed release systems, oral dosage forms, multilayer dosage form, multilayered tablets

Keywords: Modified release systems, extended release systems, controlled release systems, sustained release systems, delayed release systems, oral dosage forms, multilayer dosage form, multilayered tablets

Downloads

Download data is not yet available.

Author Biographies

Atul Pund, S.S.D.J College of Pharmacy, Chandwad, Nasik

SNJB’s SSDJ College of Pharmacy, Neminagar, Chandwad, India

Atishkumar Mundada, SNJB’s SSDJ College of Pharmacy, Neminagar, Chandwad, India

SNJB’s SSDJ College of Pharmacy, Neminagar, Chandwad, India

Manoj Magar, Blue Cross Laboratories Pvt. Ltd Nasik

Blue Cross Laboratories Pvt. Ltd Nasik, India 

Abhijeet Kadam, Bombay College of Pharmacy, Santacruz East, Mumbai, India

Bombay College of Pharmacy, Santacruz East, Mumbai, India

References

[1] Lachman L; Lieberman HA; Kanig JL. The theory and practice of industrial pharmacy. 3rd ed. Lea & Febiger; 1986.
[2] Chien Y. Novel drug delivery systems. Second. Taylor & Francis; 1991. https://doi.org/10.1201/b14196
[3] Gujral G; Kapoor D; Jaimini M. An updated review on modified release tablets. J Drug Deliv Ther, 2018; 8(4):5-9. https://doi.org/10.22270/jddt.v8i4.1722
[4] Perrie Y; Rades T. Pharmaceutics: drug delivery and targeting. Pharmaceutical Press; 2012.
[5] Barzeh H; Sogali BS; Shadvar S. A review on extended release matrix tablet. J Pharm Res, 2016; 15:147. https://doi.org/10.18579/jpcrkc/2016/15/4/108823
[6] Chen B-L; Huang C-W; Sun P-C. Extended release tablet of cyclobenzaprine. US2018116967A1, (2018).
[7] Jinturkar K; Kshirsagar R; Malaviya N; Rao A. Extended release formulation of levetiracetam. US7863316B2, (2011).
[8] Eisenreich W; Friedl T. Extended release tablet formulations of flibanserin and method for manufacturing the same. US8545886B2, (2013).
[9] Bhatt PP; Mcknight L; Muhuri G; Viera ML; Woldu AB. Orally administrable extended release pellet and tablet formulations of a highly water soluble compound. US2007134315A1, (2007).
[10] Kemeny SF; Myslinski NR; Thompson ER; Thompson ER. Extruded extended release abuse deterrent pill. US10172797B2, (2019).
[11] Mohammad MA. Disintegrating monolithic modified release tablets containing quadri-layer extended release granules. US2015283084A1, (2015).
[12] Cao L; Langridge JR; Van GAW. Extended release excipient and its use. US8865778B2, (2014).
[13] Costales GTDNJ; Francisco DMTDJ; Illa VM V; Savoir VJC. 24-hour sustained-release metoclopramide. US2011033536A1, (2011).
[14] Paiement N; Zerbe HG. Sustained-release bupropion and bupropion/mecamylamine tablets. US7674479B2, (2010).
[15] Cappola ML; Chen F-J; Sienkiewicz S; Snow GC. Extended release formulation of nevirapine. US2010278918A1, (2010).
[16] Arora S; Gandhi R; Issa C; Mathur RS; Raheja P. Extended release tablet formulation of niacin. US2010144800A1, (2010).
[17] Fanda AK; Prasad R; Singh RB; Verma RK; Vivek K. Extended release tablets of nisoldipine. US2010247646A1, (2010).
[18] Cucala EJ; Gallego LM; Margallo LI. Extended release venlafaxine besylate tablets. US7776358B2, (2010).
[19] Eisenreich W; Friedl T. Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof. US7695734B2, (2010).
[20] Abramowitz W; Dedhiya MG; Mahashabde S; Periclou A; Rao N; Rastogi SK. Modified release formulations of memantine oral dosage forms. US8039009B2, (2011).
[21] Nakhat P; Joshi V; Mandaogade P; Jain G kumar. Extended release dosage form of ropinirole. US20110262537A1, (2011).
[22] Vivek K; Fanda AK; Varshney S; Singh RB; Khurana L; Sreekanth N. Extended release pharmaceutical compositions of guanfacine hydrochloride. US20110217373A1, (2011).
[23] Bhavarisetti MK; Verma RK; Singh RB. Modified release lamotrigine tablets. US20110052686A1, (2011).
[24] Abraham J; Gupta V; Murugesan G; Shah B. Extended release dosage form of paliperidone. US2011027361A1, (2011).
[25] Sherman BC. Clarithromycin extended-release tablet. US2012219625A1, (2012).
[26] Kamble P; Kshirsagar R; Shinde G. Coated extended release pharmaceutical compositions containing paliperidone. US2012201886A1, (2012).
[27] Brueck S; Rimkus K. Retigabine tablets, preferably having modified release. US2012058183A1, (2012).
[28] Baichwal AR; Kao H-H; Lee D; Mccall T. Oxymorphone controlled release formulations. US8309122B2, (2012).
[29] Achliya GS; Bora DH; Taduri VR. Extended release formulations of desvenlafaxine base. US2013034604A1, (2013).
[30] Hoshino R; Kazama K; Nakashima K. Oral sustained-release tablet, (2013).
[31] Amidon GE; Ganorkar LD; Heimlich JM; Lee EJ; Noack RM; Reo JP; et al. Sustained-release tablet composition of pramipexole. US8399016B2, (2013).
[32] Fan H; Li C; Xie T; Zeng Z; Zhan X. Anti-tumor plant-medicament sustained-release tablet of elemene. US8778417B2, (2014).
[33] Eisenreich W; Friedl T. Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof. US2014335175A1v, (2014).
[34] Baichwal AR; Carpanzano AE; Goliber P a; Sciascia T; Vogler B; Diehl ID. Sustained release formulations of nalbuphine. US8771732B2, (2014).
[35] Devarakonda K; Giuliani MJ; Gupta VK; Heasley R a; Shelby S. Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia. US9050335B1, (2015).
[36] Chen Q-Z; Mehta H; Nelson A; Tu Y-H. Benzonatate modified release solid tablets and capsules. US9180104B2, (2015).
[37] Fathi R; Raday G. Antiemetic extended release solid dosage forms. US9636305B2, (2017).
[38] Kathala K; Perumal A; Tu Y-H. Methylphenidate extended release chewable tablet. US9545399B2, (2017).
[39] Kathala K; Perumal A; Tu Y-H. Methylphenidate extended release chewable tablet. US2020188378A1, (2020).
[40] Gaik J; Lathrop R; Nichols G; Park J; Schallom J. Extended release, abuse deterrent dosage forms. US10624888B2, (2020).
[41] Chasin M; Oshlack B. Orally administrable opioid formulations having extended duration of effect. US7270831B2, (2007).
[42] Browder M; Li B; Nangia A. Oral extended-release composition. US7476403B2, (2009).
[43] Kshirsagar R; Mundade; S; Shinde; G; Kamble; P; Sonawane; S; Mudda SM. Extended release compositions containing tolterodine and process for preparing the same. US20110123610A1, (2011).
[44] Ahmad S; Singh H; Singh RB. Extended release multiparticulates of ranolazine. US2018344653A1, (2018).
[45] Betterman SM; Patrick LM; Tantry JS. Extended-release topiramate capsules. US8889190B2, (2014).
[46] Sherman BC. Extended release dosage form comprising cyclobenzaprine hydrochloride. US2017056342A1, (2017).
[47] Betterman SM; Patrick LM; Tantry JS. Extended-release topiramate capsules. US9555005B2, (2017).
[48] Kansagra P; Patel R; Saxena M; Sehgal A; Singh B. Extended release pharmaceutical composition of clozapine. US2020054573A1, (2020).
[49] More S; Ghodekar S; Rane B; Bavaskar K; Patil M; Jain A. Multilayered tablet: a novel approach for oral drug delivery. Int J Pharm Sci Res, 2017; 9:872–82.
[50] Bunick FJ; Kriksunov LB; Luber JR; Sowden HS. Manufacture of tablet having immediate release region and sustained release region. US8313768B2, (2012).
[51] Kim KH; Lee KS; Park JS; Song WH. Pregabalin-containing, oral sustained-release triple layer tablet. US10632077B2, (2020).
[52] Cifter U; Murat UI; Oner L; Terkinli A; Turkyilmaz A. Oral tablet compositions of dexlansoprazole. US8758818B2, (2014).
[53] Jaworski TJ; Ketsela S; Sanghvi P; Sciascia T. Sustained release torsemide dosage forms. US2005169991A1, (2005).
[54] Franz M. Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin. US7303761B2, (2007).
[55] Oshlack B; Wright C; Haddox JD. Tamper-resistant oral opioid agonist formulations. US7682632B2, (2010).
[56] Meier H; Soennichsen C; Wesch R. Extended release formulation for pralnacasan. US8231904B2, (2012).
[57] Chauhan I; Nutalapati SRK. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen. US2012064159A1, (2012).
[58] Han C-H; Hou SYE; Reid ML. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic. US2012321713A1, (2012).
[59] Abebe A; Desai D; Martin K; Patel JM; Timmins P. Bilayer tablet formulations. US8535715B2, (2013).
[60] Cifter U; Oner L; Terkinli A; Turkyilmaz A; Murat UI. Dual release oral tablet compositions of dexlansoprazole. US8563034B2, (2013).
[61] Coppari M a; Fischbein G a; Meyer G a; Pastini AC; Ricci M a; Toneguzzo FG. Triple combination release multi-layered tablet. US8685451B2, (2014).
[62] Dias MC. Oral tablet formulation consisting of immediate release rosuvastatin and extended release metformin. US2020222401A1, (2020).
[63] Kube RS; Kadam VS; Shendarkar GR; Jadhav SB; Bharkad VB. Sustained release drug delivery system: review. Indian J Res Pharm Biotechnol, 2015; 3:246–51.
[64] Khatri N; Nikam S; Bilandi A. Oral osmotic drug delivery system: a review. Int J Pharm Sci Res, 2016; 7:2302–412.
[65] Ricci M a; Vergez JA. Dual controlled release dosage form. US8329217B2, (2012).
[66] Frisbee S; Mamajiwalla S. Modified release formulations of tramadol and uses thereof. WO2007078895A2, (2007).
[67] Chang C-W; Chang C-W; Huang S-W; Tsai Y-C; Wu J-S; Yang C-Y. Sustained release oral dosage form containing dalfampridine. US10172842B2, (2019).
[68] Tiwari SB; Rajabi-Siahboomi AR. Extended-release oral drug delivery technologies: monolithic matrix systems, 2008, p. 217–43. https://doi.org/10.1007/978-1-59745-210-6_11
[69] Dee KU; Mendoza WG; Santos RJM; Singh EC. Method for producing extended-release potassium citrate wax matrix tablet. US2015231267A1, (2015).
[70] Cefali E; Rocca JG; Zhu Y. Low flush niacin formulation. US2008050429A1, (2008).
[71] Kandikurwar A; Kshirsagar R; Shinde G. Extended release pharmaceutical compositions containing carbamazepine. US2014302138A1, (2014).
[72] Desai D; Phuapradit W; Shah NH; Shelke NB; Vaka SRK. Extended release compositions comprising pyridostigmine. US2019374473A1, (2019).
[73] Dragan C; Grenier P; Vergnault G. Delayed release tablet with defined core geometry. US9884021B2, (2018).
[74] Sherman BC; Spino M. Delayed release deferiprone tablets and methods of using the same. US2019125682A1, (2019).
[75] Fábregas VJL; Ruiz XN. Delayed-release tablets of methylphenidate. US2019151246A1, (2019).
[76] Bhardwaj V; Macdougall FJ; Mullen AB; Smith D; Stevens HNE. Press coated tablet prepared for delayed release of an active ingredient. US10675247B2, (2020).
[77] Sherman BC; Spino M. Delayed release deferiprone tablets and methods of using the same. US2020188309A1, (2020).
Crossmark
Statistics
710 Views | 358 Downloads
How to Cite
1.
Pund A, Mundada A, Magar M, Kadam A. Recent Patents on Modified Release Oral Dosage Forms. JDDT [Internet]. 15Aug.2021 [cited 28Mar.2024];11(4-S):195-11. Available from: https://jddtonline.info/index.php/jddt/article/view/4973